Search
                    Epilepsy Paid Clinical Trials in Iowa
A listing of 4  Epilepsy  clinical trials  in Iowa  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1 - 4 of 4
        
        
    
                The state of Iowa currently has 4 active clinical trials seeking participants for Epilepsy research studies. These trials are conducted in various cities, including Iowa City, Des Moines, Sioux City and West Des Moines. 
            
                                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    Featured Trial
                
                Cardiovascular Disease Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Cardiovascular Disease
    
    
                            Conditions: 
                                    
        
            
                        Cardiovascular Disease
                    
                                    
                
                                    A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
                                
            
            
        Recruiting
                            
            
                This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001), into both temporal lobes of subjects with drug-resistant bilateral mesial temporal lobe epilepsy.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                08/01/2025
            
            Locations: University of Iowa Health Care, Iowa City, Iowa         
        
        
            Conditions: Epilepsy, Temporal Lobe
        
            
        
    
                
                                    A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                05/07/2025
            
            Locations: Accellacare, Ames, Iowa         
        
        
            Conditions: Focal Epilepsy
        
            
        
    
                
                                    FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy
                                
            
            
        Recruiting
                            
            
                This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (NRTX-1001), into subjects with drug-resistant unilateral mesial temporal lobe epilepsy (MTLE), with or without mesial temporal sclerosis (MTS), is safe (frequency of adverse events) and effective (seizure frequency). NRTX-1001 comprises human interneurons that secrete a neurotransmitter, gamma-aminobutyric acid (GABA).             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                04/03/2025
            
            Locations: University of Iowa Health Care, Iowa City, Iowa         
        
        
            Conditions: Mesial Temporal Lobe Epilepsy
        
            
        
    
                
                                    Carbon Dioxide (CO2) Chemosensitivity and SUDEP
                                
            
            
        Recruiting
                            
            
                The purpose of this research study is to better understand what causes Sudden Unexpected Death in Epilepsy (SUDEP). This study will enroll subjects from the University of Iowa Hospitals and Clinics (UIHC) Epilepsy Monitoring Unit (EMU) and Epilepsy Clinics. The investigators will analyze the effects of seizures on breathing, on the cardiovascular system, and on arousal. The investigators are studying these effects because some cases of SUDEP might be due, in part, to an inability to wake up or s...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 99 years
            Trial Updated:
                03/10/2025
            
            Locations: University of Iowa Hospitals and Clinics, Iowa City, Iowa         
        
        
            Conditions: Epilepsy, SUDEP
        
            
        
    1 - 4 of 4
            
            
        